MedTrace Logo

Risk Evaluation and Education for Alzheimer's Disease

NCT00571025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2009-07-23

No results posted yet for this study

Summary

The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.

Conditions

Interventions

BEHAVIORAL

APOE Disclosure

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • National Human Genome Research Institute (NHGRI)

    lead NIH

Principal Investigators

  • Robert C. Green, MD, MPH · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-08-31
Completion
2004-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571025 on ClinicalTrials.gov